Drug-induced liver injury (DILI) is a major concern for drug developers, regulators, and
clinicians. However, there is no adequate model system to assess drug-associated DILI risk …

Drug-induced liver injury (DILI) is one the rare adverse drug reaction (ADR) and
multifactorial endpoints. Current preclinical animal models struggle to anticipate it, and in …

Drug-induced liver injury (DILI) has always been the focus of clinicians and drug
researchers. How to improve the performance of the DILI prediction model to accurately …

Drug-induced liver injury (DILI) has been the single most frequent cause of safety-related
drug marketing withdrawals for the past 50 years. Recently, deep learning (DL) has been …

Drug-induced liver injury (DILI) is one of the most cited reasons for the high drug attrition rate
and drug withdrawal from the market. The accumulated large amount of high throughput …

As a critical issue in drug development and postmarketing safety surveillance, drug-induced
liver injury (DILI) leads to failures in clinical trials as well as retractions of on-market …

Drug-induced liver injury (DILI), one of the most common adverse effects, leads to drug
development failure or withdrawal from the market in most cases, showing an emerging …

Drug‐induced liver injury (DILI) is one of the major causes of drug withdrawals, acute liver
injury and blackbox warnings. Clinical diagnosis of DILI is a huge challenge due to the …

Drug‐induced liver injury (DILI) is a leading cause of acute liver failure in the US and less
severe liver injury worldwide. It is also one of the major reasons of drug withdrawal from the …

Drug discovery is a costly process which usually takes more than 10 years and billions of
dollars for one successful drug to enter the market. Despite all the safety tests, drugs may …